NCT01434303View on ClinicalTrials.gov

Entinostat, Lapatinib Ditosylate and Trastuzumab in Treating Patients With Locally Recurrent or Distant Relapsed Metastatic Breast Cancer Previously Treated With Trastuzumab Only

PHASE1CompletedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

January 10, 2012

Primary Completion Date

February 16, 2016

Study Completion Date

February 16, 2016

Conditions
HER2/Neu PositiveInvasive Breast CarcinomaRecurrent Breast CarcinomaStage IV Breast Cancer AJCC v6 and v7
Interventions
DRUG

Entinostat

Given PO

OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Lapatinib Ditosylate

Given PO

BIOLOGICAL

Trastuzumab

Given IV

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT01434303 - Entinostat, Lapatinib Ditosylate and Trastuzumab in Treating Patients With Locally Recurrent or Distant Relapsed Metastatic Breast Cancer Previously Treated With Trastuzumab Only | Biotech Hunter | Biotech Hunter